Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Randomized, Double-blind, Active-controlled, Therapeutic Confirmatory, Phase III Study to Compare and Evaluate the Efficacy and Safety of Epaminurad With Febuxostat in Gout Patients

NCT05815901 is registered in ClinicalTrials.gov with JW Pharmaceutical as lead sponsor.

NCT NCT05815901
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05815901 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Randomized, Double-blind, Active-controlled, Therapeutic Confirmatory, Phase III Study to Compare and Evaluate the Efficacy and Safety of Epaminurad With Febuxostat in Gout Patients
Lead sponsor
JW Pharmaceutical
Phase
Phase 3
Overall status
Completed
Start date
March 21, 2023
Completion date
April 23, 2026
Enrollment
612 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gout